| |
-B-type Natriuretic Peptide, Whole Blood (BNPT)
-B. pertussis Ab
-B12
-B2-Transferrin, FLD (CAB2T)
-B27
-B2GP1 Antibodies G/A/M
-Babesia
-Babesia Antibodies
-Babesia G/M
-Babesia microti Antibody (BABES)
-Babesia titer
-Baby Bilirubin
-Bacterial Antigen Profile (BACG)
-Bacterial Culture, Aerobic
-Bacterial Culture, Anaerobic
-Bacterial Identification
-Bacterial Identification and Susceptibility
-Bacterial Smear
-Bactigen™
-Barbiturate Screen, Blood
-Barbiturates, Qualitative, Urine (BBIT)
-Barbiturates, Quantitative, Serum or Blood (SEHY)
-Barbiturates, Urine, GCMS (GCUB)
-Bartonella Antibody Profile (CATSD)
-Basic Metabolic Panel (BMP)
-BCAA
-BCR/ABL, Qualitative (BCR/ABLQAL (CoPath ONLY) )
-Beef Tapeworm
-Bence Jones Protein
-Bence Jones Protein, Quantitative
-Benzodiazepines, LC/MS (BENZ)
-Benzodiazepines, Qualitative, Urine (BNDZ)
-Benzodiazepines, Quant, Urine (GCUZ)
-Benzoylecgonine
-Beta Human Chorionic Gonadotropin, Serum (BHCG)
-Beta Human Chorionic Gonadotropin, Urine (URHCG)
-Beta Lipoprotein
-Beta-2-Glycoprotein-1 Autoantibody Profile (B2GP)
-Beta-Hemolytic Strep Culture, Genital
-Beta-Hemolytic Strep Culture, Throat
-Beta-Hemolytic Strep Group A Screen
-Beta-Hemolytic Strep Group B Screen
-Beta-Hydroxybutyric Acid (BHBA)
-Beta2-Microglobulin, Serum (BMIC)
-Beta2-Microglobulin, Urine (UBMIC)
-Beta2-Transferrin
-BHBâ-Hydroxybutyrate
-Bile Acids (CHLY)
-Bilirubin, Amniotic Fluid (ABIL)
-Bilirubin, Body Fluid (FTBI)
|
|
|
|
Print |
| B12 |
| |
| See Vitamin B12, Serum |
Print |
| B2GP1 Antibodies G/A/M |
| |
| See Beta-2-Glycoprotein-1Autoantibody Profile |
Print |
| B. pertussis Ab |
| |
| See Bordetella pertussis Antibody Profile |
Print |
| Babesia |
| |
| See Blood Parasites |
Print |
| Babesia Antibodies |
| |
| See Babesia microti Antibody Profile |
Print |
| Babesia G/M |
| |
| See Babesia microti Antibody Profile |
Print |
| Babesia microti Antibody |
| |
| Includes: |
IgG and IgM Antibodies |
| |
| CPT: |
86753 (x2) |
| |
| Alternate Name: |
Babesia Antibodies; Babesia G/M; Babesia Titer |
| |
| Methodology: |
Indirect Fluorescent Antibody (IFA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
Volume1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| <1:16 for both |
| |
| Clinical Utility: |
| Useful for Babesia specific IgG (greater than or equal to 1:512) is concsistent with recent infection; antibody concentrations generally peak within one month of Exposure. |
| |
Print |
| Babesia titer |
| |
| See Babesia microti Antibody Profile |
Print |
| Baby Bilirubin |
| |
| See Bilirubin, Total Neonatal (Infants <15 days old) |
Print |
| Bacterial Antigen Profile |
| |
| Includes: |
• Haemophilus influenzae Type b Antigen • Neisseria menigitidis Antigen groups A, C, Y, W135, B and E. coli K1 • Streptococcus pneumoniae Antigen • Group B/E coli K1 Ag Detection |
| |
| CPT: |
86403 (X5) |
| |
| Alternate Name: |
Bactigen™; Group B Strep Antigen, CSF; H. influenzae Type b Antigen, CSF; Neisseria meningitidis Antigen; Strep pneumoniae Antigen Methodology:Latex Agglutination Testing Schedule |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL cerebrospinal fluid |
| |
| Container: |
Sterile conical tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Negative |
| |
| Clinical Utility: |
| Useful for an aid to diagnose bacterial meningitis |
| |
Print |
| Bacterial Culture, Aerobic |
| |
| See Culture, Fluid, Aerobic |
| See Culture, Tissue, Aerobic |
| See Culture, Wound, Aerobic |
Print |
| Bacterial Culture, Anaerobic |
| |
| See Culture, Anaerobic/Aerobic |
Print |
| Bacterial Identification |
| |
| See Culture, Bacterial, Referred for Identification |
Print |
| Bacterial Identification and Susceptibility |
| |
| See Culture, Bacterial, Referred for Identification |
Print |
| Bacterial Smear |
| |
| See Gram Stain |
Print |
| Bactigen™ |
| |
| See Bacterial Antigen Profile |
Print |
| Barbiturate Screen, Blood |
| |
| See Barbiturates, Quantitative, Serum |
Print |
| Barbiturates, Quantitative, Serum or Blood |
| |
| Includes: |
• Identification and quantitation of: • Amobarbital • Butabarbital • Butalbital • Mephobarbital • Pentobarbital • Secobarbital |
| |
| CPT: |
80100 |
| |
| Alternate Name: |
Barbiturate Screen, Blood |
| |
| Methodology: |
Gas Chromatography (GC) |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
Routine: 1 day; STAT: 2 hours |
| |
| Reference Range: |
| Negative |
| |
| Clinical Utility: |
| Useful for the specific identification and quantitation of barbiturates in serum. |
| |
Print |
| Barbiturates, Qualitative, Urine |
| |
| Includes: |
Screening for barbiturates, to include: • Amobarbital • Butabarbital • Butalbital • Pentobarbital • Phenobarbital • Secobarbital |
| |
| CPT: |
80101 |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-53) Form in plastic evidence bag. |
| |
| Reference Range: |
| Negative |
| |
| Clinical Utility: |
| Useful for qualitative screen useful for detection of drug abuse/use of barbiturates. Confirmation of a positive screening result by GC/MS is strongly recommended. |
| |
Print |
| Barbiturates, Urine, GCMS |
| |
| Includes: |
identification and quantitation by GCMS: •Amobarbital •Butalbital •Pentobarbital •Phenobarbital •Secobarbital |
| |
| CPT: |
82205 |
| |
| Methodology: |
Gas Chromatography/Mass Spectroscopy (GC/MS) |
| |
| Testing Schedule: |
3 times/week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-32) Form. |
| |
| Reference Range: |
| None present |
| |
| Clinical Utility: |
| Useful for detection and positive identification of specific barbiturates in urine. |
| |
Print |
| Bartonella Antibody Profile |
| |
| Includes: |
IgG and IgM Antibodies to: Bartonella henselae Bartonella quintana |
| |
| CPT: |
86611 (x2), 86611 (x2) |
| |
| Alternate Name: |
Cat Scratch Disease Antibody Profile |
| |
| Methodology: |
Indirect Fluorescent Antibody (IFA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. eference Range: • IgG:..................<1:128 • IgM:.................<1:20 |
| |
| Clinical Utility: |
| Useful for rapid diagnosis of bartonella infections. Especially in the context of a cat scratch or Histopathology showing typical features of stellate microabscesses and/or positive Warthin-Starry stain. |
| |
Print |
| Basic Metabolic Panel |
| |
| Includes: |
• Calcium • Carbon dioxide (CO2) • Chloride • Creatinine • Glucose • Potassium • Sodium • Urea nitrogen (BUN) • Anion Gap Calculation • Glomerular Filtration Rate Calculation (GFR) |
| |
| CPT: |
80048 |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
• GFR Calculation is not performed when: ..................1. Patient is <20 years of age. ..................2. A renal steady state is not present. ..................3. Sex of patient is unkown. African-American GFR: multiply reported GFR by 1.21 |
| |
| Reference Range: |
| See individual test listings. |
| |
| Critical Values: |
| See individual test listings. |
| |
| Clinical Utility: |
| Used to evaluate blood glucose; electrolyte, fluid and acid base balances and kidney function. |
| |
Print |
| BCR/ABL, Qualitative |
| |
| Includes: |
Discrimination of the fusion transcripts related to translocations associated with CML (b2a2; b3a2; e1a2) |
| |
| Alternate Name: |
BCR/ABL Translocation |
| |
| Methodology: |
Multiplex RT-PCR Performed on the Luminex 2000 Platform |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
• Store as whole blood in original tube at room temperature • DO NOT centrifuge, aliquot or freeze |
| |
| Reference Range: |
| BCR/ABL translocation not detected. |
| |
| Clinical Utility: |
| To aid in the pathological evaluation and diagnosis of leukemia. The detection of BCR/ABL in chronic myeloid leukemia (CML) patients is useful prognostically and therapeutically. |
| |
Print |
| Beef Tapeworm |
| |
| See Parasite Identification |
Print |
| Bence Jones Protein |
| |
| See Protein Electrophoresis, Urine |
Print |
| Bence Jones Protein, Quantitative |
| |
| See Free Light Chains, Quantitative, 24- Hour Urine |
Print |
| Benzodiazepines, Qualitative, Urine |
| |
| Includes: |
Screening for benzodiazepines and metabolites, to include: • Alprazolam • Chlordiazepoxide • Diazepam • Flurazepam • Nordiazepam • Oxazepam • Temazepam |
| |
| CPT: |
80101 |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Reference Range: |
| None detected |
| |
| Clinical Utility: |
| A qualitative screen useful for detection of drug abuse/use of benzodiazepines. Confirmation of a positive screening result by GC/MS is strongly recommended. |
| |
Print |
| Benzodiazepines, Quant, Urine |
| |
| Includes: |
Identification and quantitation of benzodiazepines to include: • alpha-hydroxyalprazolam • alpha-hydroxymidazolam • diazepam • hydroxyethylflurazepam • lorazepam • nordiazepam • oxazepam • temazepam |
| |
| CPT: |
80154 |
| |
| Methodology: |
Liquid Chromatography - Tandem Mass Spectroscopy |
| |
| Testing Schedule: |
3 times/week |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-32) Form. |
| |
| Reference Range: |
| None present |
| |
| Clinical Utility: |
| Useful for the detection and positive identification of specific benzodiazepines in urine. |
| |
Print |
| Benzodiazepines, LC/MS |
| |
| Includes: |
Identification and quantitation of benzodiazepines : • alprazolam: • alpha-hydroxyalprazolam • clonazepam • 7-aminoclonazepam • chlordiazepoxide • diazepam • lorazepam • nordiazepam • oxazepam • temazepam |
| |
| CPT: |
80154 |
| |
| Methodology: |
LC/MS/MS |
| |
| Testing Schedule: |
Once per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood, serum or plasma Minimum Volume: 1 mL |
| |
| Container: |
Gray top, red, top or lavendar top tube |
| |
| Special Instructions and/or Comments: |
| Submit specimen with Chain-of-Custody if testing is for Forensic purposes. |
| |
| Reference Range: |
• alprazolam:..............................Therapeutic 10-100ng/mL • alpha-hydroxyalprazolam........Not established • clonazepam................Therapeutic 10-75ng/mL • chlordiazepoxide.......Therapeutic 400-2000 ng/mL • 7-aminoclonazepam...Concentrations following chronic therapy with 6 mg/day of clonazepan: 20-140 ng/mL • diazepam....................Therapeutic 100-1000ng/mL • lorazepam...................Therapeutic 100-1000ng/mL • nordiazepam...............Therapeutic 100-1000ng/mL • oxazepam....................Therapeutic 200-1400ng/mL • temazepam..................Peak concentrations 200-1100ng/mL |
| |
| Clinical Utility: |
| Identification and quantitation of benzodiazepine use or abuse in whole blood, serum or plasma. |
| |
Print |
| Benzoylecgonine |
| |
| See Cocaine, Qualitative, Urine |
Print |
| Beta-2-Glycoprotein-1 Autoantibody Profile |
| |
| Includes: |
IgG, IgA and IgM Beta-2- Glycoprotein-1 Autoantibodies NOTE: Testing is best utilized when performed in parallel with a Cardiolipin Autoantibody Profile. |
| |
| CPT: |
86146 (x3) |
| |
| Alternate Name: |
B2GP1 Antibodies G/A/M; Anti-Beta-2-Glycoprotein-1 Antibody Profile |
| |
| Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
• Beta-2-Glycoprotein-1 IgG:.......................<20 U/mL • Beta-2-Glycoprotein-1 IgA:.......................<10 U/mL • Beta-2-Glycoprotein-1 IgM:..................... <10 U/mL |
| |
| Clinical Utility: |
| Beta-2-GPI autoantibodies are found in patients with antiphospholipid syndrome (APS) and are associated with increased risk of venous and arterial thrombosis and thrombocytopenia. Beta2-GPI autoantibodies are found only in patients with autoimmune diseases, while cardiolipin autoantibodies can be transiently found in infectious diseases |
| |
Print |
| Beta2-Microglobulin, Serum |
| |
| CPT: |
82232 |
| |
| Methodology: |
Microparticle Enzyme Immunoassay (MEIA) |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| 0.7-3.4 mg/L |
| |
| Clinical Utility: |
Beta-2-Microglobulin is a low-molecular weight protein found on the cell surfaces of all nucleated cells and shed into the blood, particularly by tumor cells and lymphocytes. Due to its small size, it passes through the glomerular membrane, but normally less than 1% is excreted due to absorption in the proximal tubules of the kidney. Therefore, high plasma levels of BMB occur in renal failure, inflammation, and neoplasms, especially those associated with B-lymphocytes. It’s particularly useful in monitoring kidney transplant recipients. |
| |
Print |
| Beta2-Microglobulin, Urine |
| |
| Includes: |
• PH • Beta Microglobulin, Urine |
| |
| CPT: |
82232 |
| |
| Methodology: |
Nephelometry |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
Instruct patient to void, then drink full glass of water and provide urine sample within one hour. Transport to laboratory as soon as possible for Referral Testing personnel to adjust pH. |
| |
| Special Instructions and/or Comments: |
• Collect Mon.-Fri. ONLY before 1400 • No Holidays • Specimen MUST arrive in the laboratory before 1400 • Referral Testing will adjust ph of urine to between 6 & 8 usine NAOH • Refrigerate |
| |
| Reference Range: |
| <0.03 mg/L |
| |
| Clinical Utility: |
| Beta-2-microglobulin (B2M) is a low molecular-weight protein synthesized by all nuclueated cells. B2M is a clinically useful marker for following treatment response of patients with malignant lymphoma or multiple myeloma. B2M is also elevated in benign diseases; including rheumatoid arthritis, systemic lupuserythe matosus, sarcoidosis and some viral diseases. |
| |
Print |
| Beta2-Transferrin |
| |
| See Beta2-Transferrin, Cerebrospinal Fluid Associated |
Print |
| B2-Transferrin, FLD |
| |
| Includes: |
Qualitative assessment for presence of CSF-associated Beta2-Transferrin in fluid suspected to be cerebrospinal fluid in nature. |
| |
| CPT: |
86335 |
| |
| Alternate Name: |
Beta2-Transferrin; CSF- Associated Beta2-Transferrin; CSF B2T |
| |
| Methodology: |
Nepholometry |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
0.5 mL nose OR ear leakage fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Collection: |
Obtain as much fluid as possible from nose or ear leakage, avoiding contamination during collection. |
| |
| Reference Range: |
| Negative, no beta-2-transferrin (spinal fluid) detected. |
| |
| Clinical Utility: |
| Useful fo the detection of spinal fluid in body fluids, such as ear or nasal fluid |
| |
Print |
| Beta-Hemolytic Strep Culture, Genital |
| |
| See Culture, Genital, Group B, Beta- Hemolytic Strep Screen |
Print |
| Beta-Hemolytic Strep Group B Screen |
| |
| See Culture, Genital, Group B, Beta- Hemolytic Strep Screen |
Print |
| Beta-Hemolytic Strep Group A Screen |
| |
| See Culture, Throat, Group A Beta-Hemolytic Streptococci Only |
Print |
| Beta-Hemolytic Strep Culture, Throat |
| |
| See Culture, Throat, Group A Beta-Hemolytic Streptococci Only |
Print |
| Beta-Hydroxybutyric Acid |
| |
| CPT: |
82010 |
| |
| Alternate Name: |
BHB; b-Hydroxybutyrate |
| |
| Methodology: |
Spectrophotometric |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum OR plasma |
| |
| Container: |
Red top tube, Gold SST Tube OR gray top (sodium fluoride) tube |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer serum or plasma to plastic aliquot tube and refrigerate. |
| |
| Reference Range: |
• Children:......................0.02-0.29 mmol/L • Adults: .........................0.0-0.42 mmol/L |
| |
| Clinical Utility: |
| Useful for Beta-hydroxybutryrate is the predominant ketone body and is useful for the detection andmonitoring of ketoacidosis. |
| |
Print |
| Beta Human Chorionic Gonadotropin, Serum |
| |
| CPT: |
84702 |
| |
| Alternate Name: |
hCG, Beta Subunit; hCG, Quantitative; Human Chorionic Gonadotropin, Quantitative, Serum; Pregnancy Test; Quantitative Beta Subunit hCG |
| |
| Methodology: |
Direct Chemiluminescence |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
1 Gold top (serum separator) tube |
| |
| Reference Range: |
• <10 mIU/mL • Inconclusive: 5-10 mIU/mL (Inconclusive results do not rule out pregnancy. If clinically warranted, repeat testing in 48 hours.) • Gestational Age: • 0.2-1 week:..................5-50 mIU/mL • 1-2 weeks:...................50-500 mIU/mL • 2-3 weeks:...................100-5,000 mIU/mL • 3-4 weeks:...................500-10,000 mIU/mL • 4-5 weeks:...................1,000-50,000 mIU/mL • 5-6 weeks:...................10,000-100,000 mIU/mL • 6-8 weeks:...................15,000-200,000 mIU/mL • 2-3 months:.................10,000-100,000 mIU/mL NOTE: A spuriously elevated BHCG result may be obtained in the presence of heterophil antibodies. Before making a final diagnosis based on an elevated or repetitively inconclusive BHCG result, the following measures, among others, may be used in confirming results: • Perform a qualitative Beta hCG Urine test. The absence of urinary hCG may suggest a falsely elevated serum result. • Perform an additional BHCG, with the use of heterophilic antibody blocking mechanism (not FDA approved). This test must be requested by a physician as “Beta HCG with heterophilic antibody blocking mechanism” (test code BHCGH). |
| |
| Clinical Utility: |
| Used in the detection and progress of pregnancy; also used in the evaluation of some germ cell tumors. |
| |
Print |
| Beta Human Chorionic Gonadotropin, Urine |
| |
| CPT: |
81025 |
| |
| Alternate Name: |
hCG, Qualitative, Urine; hCG, Urine; Human Chorionic Gonadotropin, Urine; Pregnancy Test; Qualitative Beta Subunit hCG, Urine; Urine Pregnancy Test |
| |
| Methodology: |
Membrane Based Enzyme Immunoassay |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
NOTE: The first morning urine generally contains the highest concentration of hormone. |
| |
| Special Instructions and/or Comments: |
| Testing is contraindicated on bloody specimens. |
| |
| Reference Range: |
Negative NOTE: This assay can detect levels of BHCG as low as 20 mIU/mL. A negative test may result from a very early pregnancy with low levels of BHCG or a urine specimen which is too dilute. If pregnancy is still suspected, the test should be repeated on a fresh specimen in 2-4 days. |
| |
| Clinical Utility: |
| Primarily used for the confirmation of pregnancy. Urine hCG tests usually suffice for diagnosis of normal pregnancy when it has progressed beyond the first week after the first missed period. |
| |
Print |
| Beta Lipoprotein |
| |
| See LDL Cholesterol, Direct |
Print |
| BHBâ-Hydroxybutyrate |
| |
| See Beta-Hydroxybutyric Acid |
Print |
| Bile Acids |
| |
| CPT: |
82239 |
| |
| Alternate Name: |
Cholyglycine |
| |
| Methodology: |
Enzymatic |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Collection: |
Overnight fast required (8 hours, minimum) |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer to plastic aliquot tube and refrigerate. |
| |
| Reference Range: |
| 0.0-10.0 umol/L |
| |
| Clinical Utility: |
| Bile Acids arer formed in the liver, from Cholesterol, stored and concentrated in the gallbladder, and excreted into the intestines in response to food. Elevated concentrations often suggest impaired hepatic clearance due to liver disease. Patients with intestinal malabsorption and metabolic disorders such as Gilbert’s disease do not exhibit elevated Bile Acids concentrations. |
| |
Print |
| Bilirubin, Amniotic Fluid |
| |
| Includes: |
Delta OD 450 spectral analysis |
| |
| CPT: |
82143 |
| |
| Alternate Name: |
Amniotic Fluid Analysis for Erythroblastosis Fetalis; Amniotic Fluid Bilirubin; Delta OD 450 |
| |
| Methodology: |
Spectrophotometric |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL amniotic fluid |
| |
| Container: |
Brown glass or plastic container |
| |
| Collection: |
Amniocentesis performed by physician |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Requisition must include weeks of gestation information. • Protect from light by wrapping the entire container with aluminum foil. |
| |
| Clinical Utility: |
| Useful for determining the presence of fetal erythroblastosis. |
| |
Print |
| Bilirubin, Body Fluid |
| |
| CPT: |
82247 |
| |
| Alternate Name: |
Body Fluid TBIL |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL body fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
| Protect from light by wrapping the entire tube with aluminum foil. |
| |
| Reference Range: |
| None established, must be interpreted with clinical findings. |
| |
Print |
| Bilirubin, Conjugated |
| |
| See Bilirubin, Direct, (Infants 15 days to adults) |
| See Bilirubin, Direct Neonatal, (Infants <15days old) |
Print |
| Bilirubin, Direct (Infants 15 days to adults) |
| |
| CPT: |
82248 |
| |
| Alternate Name: |
Bilirubin, Conjugated; Delta; Direct Bilirubin |
| |
| Methodology: |
HNL..................Endpoint LPP...................Bichromatic endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
• Infant:..........................0.1 mL serum • Adult:..........................1.0 mL serum |
| |
| Container: |
Gold top (serum separator) tube OR yellow, green or red BD Microtainer™ tube |
| |
| Collection: |
Avoid hemolysis. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Protect from light by wrapping the entire tube with aluminum foil. NOTE: To maintain consistency in Bilirubin methodology, an infant who has had a Bilirubin, Direct Neonatal ordered and becomes >14 days old, should continue to have a Bilirubin, Direct Neonatal ordered– DO NOT SWITCH TO THE BILIRUBIN, DIRECT. |
| |
| Reference Range: |
| 0.0-0.4 mg/dL |
| |
| Clinical Utility: |
Used in the evaluation of hepatic, biliary and hemolytic disorders. |
| |
Print |
| Bilirubin, Direct Neonatal (Infants <15 days old) |
| |
| CPT: |
82248 |
| |
| Alternate Name: |
Bilirubin, Conjugated; Direct Bilirubin |
| |
| Methodology: |
HNL...............Endpoint LPP................Bichromatic endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
0.1 mL serum |
| |
| Container: |
Yellow, green OR red BD Microtainer™ tube |
| |
| Collection: |
• Collect by heelstick. • Avoid hemolysis. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Protect from light by wrapping the entire tube with aluminum foil. NOTE: To maintain consistency in Bilirubin methodology, an infant who has had a Bilirubin, Direct Neonatal ordered and becomes >14 days old, should continue to have a Bilirubin, Direct Neonatal ordered– DO NOT SWITCH TO THE BILIRUBIN, DIRECT. |
| |
| Reference Range: |
| 0.0-1.5 mg/dL |
| |
| Clinical Utility: |
| Used in the evaluation of hepatic, biliary and hemolytic disorders. |
| |
Print |
| Bilirubin, Total Neonatal (Infants <15 days old) |
| |
| CPT: |
82247 |
| |
| Alternate Name: |
Baby Bilirubin; Microbilirubin, Total; Total Bilirubin, Neonatal |
| |
| Methodology: |
HNL....................... Endpoint LPP.........................Bichromatic endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
0.1 mL serum |
| |
| Container: |
Yellow, green OR red BD Microtainer™ tube |
| |
| Collection: |
• Collect by heelstick. • Avoid hemolysis. |
| |
| Special Instructions and/or Comments: |
| • Transport to the laboratory immediately.• Protect from light by wrapping the entire tube with aluminum foil. NOTE: To maintain consistency in Bilirubin methodology, an infant who has had a Bilirubin, Total Neonatal ordered and becomes >14 days old, should continue to have a Bilirubin, Total Neonatal ordered– DO NOT SWITCH TO THE BILIRUBIN, TOTAL. |
| |
| Reference Range: |
• 0 days:..............................0.2-5.0 mg/dL • 1 day: ..............................0.2-9.0 mg/dL • >2 days: ...........................0.2-13.0 mg/dL • >7 days:............................0.2-1.3 mg/dL |
| |
| Critical Values: |
| >15.0 mg/dL |
| |
| Clinical Utility: |
| Used in the evaluation of hepatic, biliary and hemolytic disorders. |
| |
Print |
| Bilirubin, Total (Infants 15 days to adults) |
| |
| CPT: |
82247 |
| |
| Alternate Name: |
Total Bilirubin |
| |
| Methodology: |
HNL:................Endpoint LPP:.................Bichromatic endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
• Infant: 0.1 mL serum • Adult: 1 mL serum |
| |
| Container: |
Gold top (serum separator) tube OR yellow, green or red BD Microtainer™ tube |
| |
| Collection: |
Avoid hemolysis. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Protect from light by wrapping the entire tube with aluminum foil. NOTE: To maintain consistency in Bilirubin methodology, an infant who has had a Bilirubin, Total Neonatal ordered and becomes >14 days old, should continue to have a Bilirubin, Total Neonatal ordered– DO NOT SWITCH TO THE BILIRUBIN, TOTAL. |
| |
| Reference Range: |
| 0.2-1.3 mg/dL |
| |
| Critical Values: |
| >15.0 mg/dL |
| |
| Clinical Utility: |
| Used in the evaluation of hepatic, biliary and hemolytic disorders. |
| |
Print |
| Bilirubin, Urine |
| |
| CPT: |
81002 |
| |
| Alternate Name: |
Ictotest for Bilirubin |
| |
| Methodology: |
Manual |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
• Refrigerate • Protect from light by wrapping the entire container with aluminum foil. |
| |
| Reference Range: |
| Negative |
| |
| Clinical Utility: |
| Used as a screen for hepatic and biliary disorders and obstruction. |
| |
Print |
| Biopsy |
| |
| See Histopathology |
Print |
| Biopsy, Breast |
| |
| See Histopathology, Breast Biopsy |
Print |
| Biopsy, Culture |
| |
| See Culture, Tissue, Aerobic |
Print |
| Biopsy Culture, Aerobic |
| |
| See Culture, Tissue, Aerobic |
Print |
| Biopsy Specimen Culture, Quantitative |
| |
| See Culture, Tissue, Quantitative |
Print |
| BJP (Bence Jones Protein) |
| |
| See Protein Electrophoresis, Urine |
Print |
| BK Virus, PCR, Blood |
| |
| CPT: |
87799 |
| |
| Methodology: |
Polymerase Chain Reaction (PCR) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL EDTA whole blood |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
• Store as whole blood in original tube. • DO NOT centrifuge, aliquot, or freeze. • Refrigerate only. |
| |
| Reference Range: |
| Not detected. If detected the result is quantitative |
| |
| Clinical Utility: |
| Useful for assessment of active BK Virus infection. |
| |
Print |
| BK Virus, PCR, Urine |
| |
| CPT: |
87799 |
| |
| Methodology: |
Polymerase Chain Reaction (PCR) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5-10 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| Refrigerate. |
| |
| Reference Range: |
| Not detected. If detected the result is quantitative. |
| |
| Clinical Utility: |
| Useful for assessment of active BK Virus infection. |
| |
Print |
| Bladder Washings Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Bleeding Time |
| |
| See Bleeding Time, Template |
Print |
| Bleeding Time, Template |
| |
| CPT: |
85002 |
| |
| Alternate Name: |
Bleeding Time; Capillary Bleeding Time; Ivy Bleeding Time; Mielke Bleeding Time; Template Bleeding Time |
| |
| Methodology: |
Standardized Incision |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
Flowing blood from lancet incision. |
| |
| Container: |
Filter paper |
| |
| Collection: |
NOTE: This collection procedure is performed by laboratory designated personnel only. 1 mm deep (pediatric 0.5 mm) incision is made on the volar surface of the forearm using a lancet specified for TBT testing. Welling blood is removed at 30 second intervals using filter paper without disturbing the platelet plug. Constant venous pressure of 40 mmHg for adults and 20 mmHg for children (<12 years old) is applied throughout the procedure. Testing is discontinued after 15 minutes if bleeding does not cease. |
| |
| Special Instructions and/or Comments: |
| Platelet count must be >100,000/cumm to perform test. Medication containing aspirin should be suspended at least 1 week prior to testing. |
| |
| Reference Range: |
| Adults & Children:.........2-8 minutes |
| |
| Critical Values: |
| >15 minutes |
| |
| Clinical Utility: |
| Used as a screening for coagulation abnormality; in particular to assess capillary and platelet function. |
| |
Print |
| Blood Acetone |
| |
| See Acetone, Semiquantitative |
Print |
| Blood Ammonia |
| |
| See Ammonia, Plasma |
Print |
| Blood Culture |
| |
| See Culture, Blood |
Print |
| Blood Culture, Aerobic/Anaerobic |
| |
| See Culture, Blood |
Print |
| Blood Culture, AFB |
| |
| See Culture, Blood, Mycobacteria |
Print |
| Blood Culture, Bacterial |
| |
| See Culture, Blood |
Print |
| Blood Culture, Fungus |
| |
| See Culture, Blood, Fungus |
Print |
| Blood Culture, TB |
| |
| See Culture, Blood, Mycobacteria |
Print |
| Blood Culture, MAI |
| |
| See Culture, Blood, Mycobacteria |
Print |
| Blood Gas, Arterial |
| |
| Includes: |
• % oxygen saturation (sO2) • pH • pCO2 • pO2 • Bicarbonate (HCO3), Standard • Base excess or deficit, standard • TCO2 |
| |
| CPT: |
82805 |
| |
| Alternate Name: |
ABG |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
STAT testing only |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
• Pediatric: 100 µL heparinized (lithium heparin) arterial whole blood • Adult: 3 mL heparinized (lithium heparin) arterial whole blood |
| |
| Container: |
Heparinized blood gas syringe OR heparinized glass capillary tubes NOTE: It is impossible to maintain anaerobic integrity of a specimen if evacuated glass tubes are used. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Must be tested within 30 minutes of collection • Collection sites listed in order of preference are: radial, brachial, and femoral arteries. |
| |
| Reference Range: |
• pH:..............................7.35-7.45 • pCO2: < 24 months..........27-40 mm Hg < 24 months Male.................35-48 mmHg Female..............32-45 mm/Hg • pO2: .........................>70 mm Hg Birth......................8-24 mm/Hg 5-10 min...............33-75 mm/Hg 30 min..................31-85 mm/Hg > 1 Hr...................55-80 mm/Hg 1 day.....................54-95 mm/Hg > 1 day..................83-108 mm/Hg • HCO3: ........................22-28 mEq/L < 2 mos................17-2 mEq/L 2 mos-2 yr............16-2 mEq/L Adult....................21-28 mEq/L • TCO2: ........................22-28 mEq/L < 2 mos................13-22 mEq/L 2 mos-19 yr..........20-28 mEq/L Adult >19.............22-29 mEq/L >60 yrs..................22-28 mEq/L • sO2: < 2 month:............40-90% > 2 month:............95-998 |
| |
| Critical Values: |
• pH: ......................<7.20 or >7.55 • pCO2:...................<20 mm Hg or >60 mm Hg • pO2: .....................<60 mm Hg • TCO2:...................<15 or >40 mEq/L |
| |
| Clinical Utility: |
Used to evaluate oxygenation, cardiorespiratory function and acid/base balance. |
| |
Print |
| Blood Gas, Arterial Cord Blood |
| |
| Includes: |
• pH • pCO2 • Bicarbonate (HCO3), Standard • Base excess or deficit, standard |
| |
| CPT: |
82803 |
| |
| Alternate Name: |
Cord Blood Gas |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
STAT testing only |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL heparinized (lithium heparin) arterial cord whole blood |
| |
| Container: |
Heparinized blood gas syringe |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Must be tested within 30 minutes of collection. |
| |
| Reference Range: |
• pH:..............................7.26-7.50 • pCO2: ........................33-65 mm Hg • HCO3:........................17-27 mEq/L |
| |
| Clinical Utility: |
Used to assess newborn respiratory status. |
| |
Print |
| Blood Gas, Arterial with Co-oximetry |
| |
| Includes: |
• Arterial blood gas • Carboxyhemoglobin • Methemoglobin • Oxyhemoglobin • Total Hemoglobin, Calculated • O2 Content |
| |
| CPT: |
82805, 83050:, 82375 |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
STAT testing only |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL heparinized (lithium heparin) arterial whole blood |
| |
| Container: |
Heparinized blood gas syringe |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Must be tested within 30 minutes of collection. |
| |
| Reference Range: |
• pH: ...............................7.35-7.45 • pCO2: < 24 months.........27-40 mm Hg < 24 months Male................35-48 mmHg Female............32-45 mm/Hg • pO2: ..........................>70 mm Hg Birth....................8-24 mm/Hg 5-10 min.............33-75 mm/Hg 30 min.................31-85 mm/Hg > 1 Hr..................55-80 mm/Hg 1 day...................54-95 mm/Hg > 1 day................83-108 mm/Hg • HCO3: .......................22-28 mEq/L Adult...................21-28 mEq/L • TCO2: .......................22-28 mEq/L < 2 mos...............13-22 mEq/L 2 mos-19 yr.........20-28 mEq/L Adult >19............22-29 mEq/L >60 yrs................22-28 mEq/L • sO2: < 2 month: .........40-90% • O2 Content: ...............15-33 mL/dL • Carboxyhemoglobin: •>2 pks/d.............8-9% |
| |
| Critical Values: |
• pH:...........................<7.20 or >7.55 • pCO2:.........................<20 or >60 mm Hg • pO2:............................<60 mm Hg • TCO2:.........................<15 or >40 mEq/L • Carboxyhemoglobin:..>20% |
| |
| Clinical Utility: |
| Used to evaluate cardiorespiratory function, acid/base balance, inhalation injury and oxygen saturation. |
| |
Print |
| Blood Gas, Arterial/Venous Oxygen Saturation Difference |
| |
| Includes: |
• Blood Gas, Arterial • Blood Gas, Venous • Oxygen saturation difference |
| |
| CPT: |
82805 (x2) |
| |
| Alternate Name: |
AVO2 |
| |
| Testing Schedule: |
STAT testing only |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL heparinized (lithium heparin) arterial whole blood AND 3 mL heparinized venous whole blood |
| |
| Container: |
Heparinized blood gas syringe |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Must be tested within 30 minutes of collection. |
| |
| Reference Range: |
Content difference: 4.5-5.5 volume % O2 NOTE: The AVO2 Difference is the oxygen difference in volume percent between arterial and venous blood samples. • An increased AVO2 Difference: May reflect more complete extraction of oxygen from the blood as is characteristic in tissues receiving decreased blood flow (i.e., CHF, shock) • A decreased AVO2 Difference: may reflect less extraction of oxygen from the blood than normal (i.e.,sepsis, high cardiac output). |
| |
| Clinical Utility: |
Used to measure the oxygen difference between arterial and venous blood samples. |
| |
Print |
| Blood Gas, Venous |
| |
| Includes: |
• pH • pCO2 • pO2 • % oxygen saturation (sO2) • Bicarbonate (HCO3), Standard • Base excess or deficit, standard |
| |
| CPT: |
82805 |
| |
| Alternate Name: |
VBG; Venous Blood Gas |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
STAT testing only |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Container: |
3 mL heparinized (lithium heparin) venous cord blood Container:Heparinized blood gas syringe OR green top (lithium heparin) tube |
| |
| Collection: |
Collect specimen into air free heparinized syringe or green top (lithium heparin) tube NOTE: If a green top tube is used, the tube must be removed from the Vacutainer® holder prior to the needle being removed from the patient’s arm. |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory immediately. |
| |
| Reference Range: |
• Venous pCO2: • 0-15 days:............10-25 mm Hg • >15 days:.............40-50 mm Hg • pH: .................................7.33-7.43 • pO2:...............................approximately 40 mm Hg • sO2:...............................approximately 75% |
| |
| Clinical Utility: |
| Useful for evaluating cellular hypoxia and acid/base balance. |
| |
Print |
| Blood Gases, Venous Cord Blood |
| |
| Includes: |
• pH • pCO2 • Bicarbonate (HCO3), Standard • Base excess or deficit, standard |
| |
| Alternate Name: |
Cord Blood VBG |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
STAT testing only |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL heparinized (lithium heparin) venous cord blood |
| |
| Container: |
Heparinized blood gas syringe |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory immediately. |
| |
| Reference Range: |
• pH: ....................7.22-7.46 • pCO2:.................32.8-48.6 mm Hg • HCO3:................18.9-23.9 mEq/L |
| |
| Clinical Utility: |
| Used to evaluate cellular hypoxia and acid/base balance in the newborn. |
| |
Print |
| Blood Grouping and Rh Typing |
| |
| See ABO and Rh (D) Type |
Print |
| Blood Lactate |
| |
| See Lactate, Plasma |
Print |
| Blood NH3 |
| |
| See Ammonia, Plasma |
Print |
| Blood NH4 |
| |
| See Ammonia, Plasma |
Print |
| Blood, Occult, Stool |
| |
| See Occult Blood, Stool |
Print |
| Blood Parasites |
| |
| Includes: |
Examination of both thick and thin smears |
| |
| CPT: |
87207 |
| |
| Alternate Name: |
Blood Smear for Trypanosomal/Filarial Parasites; Parasitology Examination for Malaria; Plasmodium Smear; Babesia |
| |
| Methodology: |
Giemsa Stain |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
6 slides (3 thick AND 3 thin) |
| |
| Container: |
Slides. NOTE: Blood may be collected using a lavender top vacutainer. Smears must be made within 30 minutes of collection. Smears made at time of collection are preferred. |
| |
| Collection: |
Collect blood from venipuncture NOTE: Recommended procedure is for specimen to be obtained when patient spikes a fever. Optimal yield results from examination of a daytime specimen (ie, noon) and a night-time specimen (ie, midnight). Timing of sampling relates to geographic place of exposure. |
| |
| Special Instructions and/or Comments: |
| If patient has traveled to an endemic area, the date of travel, area traveled and parasite suspected should be specified on the Requisition Form. |
| |
| Reference Range: |
| Negative. If positive, organism is identified. |
| |
| Clinical Utility: |
| A number of parasites can be recovered from blood specimens. These parasites include Plasmodium, Babesia, Trypanosoma, Leishmania, Toxoplasma and microfilariae. Species identification is accomplished by the reading of permanent blood smears. Identification of a parasite aids in patient diagnosis and treatment. |
| |
Print |
| Blood Smear for Trypanosomal/Filarial Parasites |
| |
| See Blood Parasites |
Print |
| Blood Type |
| |
| See ABO and Rh (D) Type Blood Type |
| See ABO and Rh (D) Type, Directed Donor |
Print |
| Blood Urea Nitrogen |
| |
| See Urea Nitrogen, Serum |
Print |
| BNP, Congestive Heart Failure Test |
| |
| See B-type Natriuretic Peptide, Whole Blood |
Print |
| Body Cavity Fluid Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Body Fluid Albumin |
| |
| See Albumin, Body Fluid |
Print |
| Body Fluid Amylase |
| |
| See Amylase, Body Fluid |
Print |
| Body Fluid BUN |
| |
| See Urea Nitrogen, Body Fluid |
Print |
| Body Fluid Cell Count |
| |
| See Cell Count, Body Fluid |
Print |
| Body Fluid Creatinine |
| |
| See Creatinine, Body Fluid |
Print |
| Body Fluid Culture |
| |
| See Culture, Fluid, Aerobic |
Print |
| Body Fluid Electrolytes |
| |
| See Electrolytes, Body Fluid |
Print |
| Body Fluid Glucose |
| |
| See Glucose, Body Fluid |
Print |
| Body Fluid K |
| |
| See Potassium, Body Fluid |
Print |
| Body Fluid LDH |
| |
| See Lactate Dehydrogenase, Body Fluid |
Print |
| Body Fluid pH |
| |
| See pH, Body Fluid |
Print |
| Body Fluid Potassium |
| |
| See Potassium, Body Fluid |
Print |
| Body Fluid Protein |
| |
| See Protein, Total, Body Fluid |
Print |
| Body Fluid Sodium |
| |
| See Sodium, Body Fluid |
Print |
| Body Fluid TBIL |
| |
| See Bilirubin, Body Fluid |
Print |
| Body Fluid Uric Acid |
| |
| See Uric Acid, Body Fluid |
Print |
| Bone Alkaline Phosphatase |
| |
| See Alkaline Phosphatase, Bone Specific |
Print |
| Bordetella Abs |
| |
| See Bordetella pertussis Antibody Profile |
Print |
| Bordetella titer |
| |
| See Bordetella pertussis Antibody Profile |
Print |
| Bordetella pertussis Antibody Profile |
| |
| Includes: |
PT IgG, and IgA, FHA IgG and IgA |
| |
| CPT: |
86615 (x4) |
| |
| Alternate Name: |
Bordetella Abs; Bordetella titer; B. pertussis Ab; Pertussis Antibody Profile |
| |
| Methodology: |
Multi-Analyte Immunodetection (MAID) Testing Schedule: Routine, Mon. - Fri. |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• PT IgG........................<40 units/mL • PT IgA.......................<5 units/mL • FHA IgG....................<84 units/mL • FHA IgA...................<39 units/mL |
| |
| Clinical Utility: |
| Levels of antibodies recognizing pertussis toxin (PT) and filamentous hemagglutinin antigen (FHA) are typically increased following either vaccination or natural exposure to Bordetella pertussis. Increased levels of FHA IgG alone may represent crossreactive antibodies induced by infection with other Bordetella species, Mycoplasma pneumoniae, Chlamlydia pneumoniae or nonencapsulated Haemophilus influenzae. |
| |
Print |
| Bordetella, PCR |
| |
| Includes: |
B.pertussis and B. parapertussis |
| |
| CPT: |
87801, 83907 |
| |
| Alternate Name: |
Bordetella Pertussis/ Parapertussis, Pertussis,PCR, Whooping Cough |
| |
| Methodology: |
Realtime PCR |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Collection: |
Nasopharyngeal nylon flocked swab placed in universal transport media (UTM), refrigerate OR Nasopharyngeal Aspirate (not throat), frozen. |
| |
| Special Instructions and/or Comments: |
| DO NOT use calcium- alginate swabs |
| |
| Reference Range: |
| Not detected |
| |
| Clinical Utility: |
| Bordetella DNA detection by PCR has a greater than 2-fold higher specificity than culture and can detect the presence of bacterial nucleic acid from non—viable pathogens compromised by either transit or antibiotic therapy. |
| |
Print |
| Borrelia burgdorferi Antibodies |
| |
| See Lyme Disease Antibody Profile |
Print |
| Borrelia burgdorferi C6 Peptide Antibody |
| |
| See Lyme C6 Peptide Antibody |
Print |
| Borrelia burgdorferi PCR, Blood |
| |
| See Lyme, PCR, Blood |
Print |
| Borrelia burgdorferi PCR, CSF |
| |
| See Lyme, PCR, Cerebrospinal Fluid |
Print |
| Borrelia burgdorferi Western Blot |
| |
| See Lyme Disease Antibody,Western Blot |
Print |
| Brain type Natriuretic Peptide |
| |
| See B-type Natriuretic Peptide,Whole Blood |
Print |
| Breast Aspiration Cytology |
| |
| See Cytopathology, Needle Aspiration |
Print |
| Breast Cancer Antigen |
| |
| See CA 15-3 |
Print |
| Bromide, Blood |
| |
| CPT: |
84311 |
| |
| Methodology: |
Colorimetry |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL EDTA whole blood |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
• Store as whole blood in original tube. • DO NOT centrifuge, aliquot, or freeze. • Refrigerate only. |
| |
| Reference Range: |
• Therapeutic:.................1,000-2,000 µg/mL • Toxic:...........................> 3,000 µg/mL |
| |
| Clinical Utility: |
| Useful for support of the serodiagnosis of brucellosis. |
| |
Print |
| Bronchial Brushing Smears |
| |
| See Cytopathology, Direct Smears |
Print |
| Bronchial Brush Rinse Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Bronchial Washing Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Bronchoscopy, Culture, Bacterial |
| |
| See Culture, Bronchoscopy |
Print |
| Bronchoscopy, Culture, Bacterial |
| |
| See Culture, Bronchoscopy |
Print |
| Brucella abortus Antibody Profile |
| |
| Includes: |
IgG, and IgM Antibodies |
| |
| CPT: |
86622 x 3 |
| |
| Alternate Name: |
Brucella Antibody; Brucella Titer |
| |
| Methodology: |
ELISA |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Brucella IgG & IgM:........< .80U |
| |
| Clinical Utility: |
| Useful for support of the serodiagnosis of brucellosis. |
| |
Print |
| Brucella Antibody |
| |
| See Brucella abortus Antibody Profile |
Print |
| Brucella Titer |
| |
| See Brucella abortus Antibody Profile |
Print |
| B-type Natriuretic Peptide, Whole Blood |
| |
| CPT: |
83880 |
| |
| Alternate Name: |
BNP, Congestive Heart Failure Test; Brain type Natriuretic Peptide |
| |
| Methodology: |
Direct Chemiluminescence |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
• Refrigerate uncentrifuged tube. • Must be tested within 24 hours of collection. • If delay in transport, centrifuge, transfer plasma plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| <100 pg/mL |
| |
| Clinical Utility: |
| Used in the evaluation of congestive heart failure. |
| |
Print |
| Bullous Pemphigoid Antibodies |
| |
| See Histopathology, Skin Biopsy, Immunofluorescence |
Print |
| BUN |
| |
| See Urea Nitrogen, Serum |
Print |
| Buprenorphine |
| |
| Includes: |
Screen for buprenorphine and norbuprenorphine, cutoff concentration 5ng/ml |
| |
| CPT: |
80101 |
| |
| Alternate Name: |
Suboxone, Subutex |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
• This is a qualitative screen and result is reported as positive or negative. • Confirmation of a positive screening result by GC/MS or LC/MS is available upon request by calliong the Toxicology Lab at (610) 402-5850 • Chain of Custody optional |
| |
| Reference Range: |
| Negative, unless taking buprenorphine |
| |
| Clinical Utility: |
| Detect the ingestion and/or use of buprenorphine for monitoring compliance or drug abuse |
| |
Print |
| Buproprion |
| |
| Includes: |
• Buproprion • Hydroxybuproprion |
| |
| CPT: |
82491 |
| |
| Alternate Name: |
Wellbutrin |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
• Refrigerate • Centrifuge tube and transfers serum to plastic vial |
| |
| Reference Range: |
Suggested Therapeutic range: • Buproprion:.....................50-100 ng/mL • Hydroxybuproprion:........600-2000 ng/mL |
| |
Print |
| Burn Culture |
| |
| See Culture, Burn Wound |
Print |
| Burn Culture, Quantitative |
| |
| See Culture, Tissue, Quantitative |
Print |
| Butalbital |
| |
| CPT: |
82205 |
| |
| Alternate Name: |
Fioricet; Fiorinal |
| |
| Methodology: |
Gas Chromatography |
| |
| Testing Schedule: |
Routine, 2 times a week; STAT testing available |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
• Therpeutic:...................1-10 µg/mL • Toxic: ..........................7-40 µg/mL |
| |
| Clinical Utility: |
| Useful for the identification and quantitation of butalbital in serum to asses toxicity or monitoring therapeutic range or possible abuse. |
| |
|